{
    "nct_id": "NCT03922204",
    "official_title": "A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies",
    "inclusion_criteria": "* Histologically or cytologically confirmed advanced or recurrent/metastatic solid tumors or B-cell lymphomas, that are considered non-amenable to surgery or other curative treatments or procedures (if applicable)\n* Measureable disease per RECIST v1.1 or Lugano Criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Received prior standard therapy for advanced or recurrent/metastatic disease as applicable to tumor type\n* Received a maximum of 4 prior systemic treatment regimens (inclusive of chemotherapy, immunotherapy, and targeted therapy regimens) for advanced or recurrent/metastatic disease\n* Life expectancy of ≥12 weeks, as per investigator judgement\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* The following B-cell neoplasms: Burkitt lymphoma, lymphoblastic leukemia/lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia\n* Prior therapy containing an anti-PD-L1 agent or T-cell agonist\n* Current serious illness or medical condition including, but not limited to uncontrolled active infection\n* Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting MCLA-145\n* Prior ≥ Grade 3 immune-mediated AEs with anti-PD-1 therapy\n* History of any grade immune-mediated ocular AEs.\n* Known hypersensitivity or severe reaction to any component of MCLA-145 or formulation components\n* Participants who have active or inactive autoimmune disease or syndrome (eg, rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease) that has required systemic treatment in the past 2 years or who are receiving systemic therapy for an autoimmune or inflammatory disease (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)",
    "miscellaneous_criteria": ""
}